Skip to main
INSP

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 18%
Buy 53%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Inspire Medical Systems has demonstrated significant growth potential as evidenced by a notable 56% increase in spending in the third quarter of 2025, with expectations for continued investment into 2026, which historically has driven awareness and procedural uptake. The company's advertising expenses rose to $100 million in 2023, a 34% year-over-year increase, indicating a strong commitment to expanding market presence and supporting revenue growth. Additionally, management has indicated plans to increase average selling prices (ASP) starting in calendar year 2026 alongside improved reimbursement prospects, which could lead to higher volumes and enhanced profitability.

Bears say

Inspire Medical Systems is facing a negative outlook primarily due to a slowdown in advertising expenditures, which decreased by 5% year-over-year for 2024 and are projected to decline by 6% in the first half of 2025. The anticipated launch of the Inspire 5 product has encountered challenges that have prompted management to lower its revenue and earnings per share outlook, indicating a slower adoption than previously expected. Furthermore, operational expenditures were less than industry expectations, primarily due to significant cuts in research and development and selling, general, and administrative expenses, raising concerns about the company's growth trajectory and overall stock valuation.

INSP has been analyzed by 17 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 53% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 17 analysts, INSP has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $136.35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $136.35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.